Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including melanoma. “Immune checkpoint inhibitors play a vital role in the treatment ...

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky ...

In other recent news, Immuneering Corp announced significant progress in its ongoing Phase 2a clinical trials involving IMM-1-104, a treatment for advanced RAS-mutant solid tumors. The trials ...

The company’s lead pipeline candidate is IMM-1-104, an investigational RAS medication, which is being evaluated in a phase I/IIa study in patients with advanced solid tumors harboring RAS mutations.

Specifically, the company plans to present: Additional data from IMM-1-104 in combination with mGnP in first-line pancreatic cancer. Initial data from IMM-1-104 in combination with mFFX in first ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...